Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
23andMe CEO Anne Wojcicki Plans to Take Company Private
23andMe CEO Anne Wojcicki Plans to Take Company Private
The DNA-testing company’s enterprise value is less than zero as its shares close at a new low
By
Rolfe Winkler
Follow
Updated April 17, 2024 9:12 pm ET
23andMe’s stock closed at a new low of 36 cents a share Wednesday. PHOTO: TIFFANY HAGLER-GEARD/BLOOMBERG NEWS
Snip...after three years in public markets that saw the once-hot company’s valuation collapse from a high of $6 billion.
Snip...she is working with advisers to help craft a potential deal and intends to speak with potential partners and financing sources. The filing said she would oppose any other buyer taking over the company. She holds 49.99% voting power in the company, which would make it all but impossible for anyone else to buy it.
23andMe’s stock closed at 36 cents a share on Wednesday, a new low that translates to a market capitalization of about $200 million. 23andMe had more than that amount of cash in the bank at the end of last quarter, meaning the company’s enterprise value is negative.
Snip...DNA tests aren’t as popular as they once were and lose money. Snip... since customers only need to take its test once.
Wojcicki pivoted the company into prescription drug development, hoping to use its massive DNA database to discover new pharmaceuticals. But drug discovery is a cash-hungry business in which prospects can take a decade to pay off. The company has enough cash to last until 2025 at its current rate of spending. It has potential drug candidates in the pipeline, and taking the company private while securing additional financing could give it more leeway to get them to market.
Snip...more...
https://archive.ph/WOUeO
https://www.wsj.com/tech/biotech/23andme-ceo-anne-wojcicki-plans-to-take-company-private-1a9265eb?mod=WTRN_pos2&cx_testId=3&cx_testVariant=cx_167&cx_artPos=1
The DNA-testing company’s enterprise value is less than zero as its shares close at a new low
By
Rolfe Winkler
Follow
Updated April 17, 2024 9:12 pm ET
23andMe’s stock closed at a new low of 36 cents a share Wednesday. PHOTO: TIFFANY HAGLER-GEARD/BLOOMBERG NEWS
Snip...after three years in public markets that saw the once-hot company’s valuation collapse from a high of $6 billion.
Snip...she is working with advisers to help craft a potential deal and intends to speak with potential partners and financing sources. The filing said she would oppose any other buyer taking over the company. She holds 49.99% voting power in the company, which would make it all but impossible for anyone else to buy it.
23andMe’s stock closed at 36 cents a share on Wednesday, a new low that translates to a market capitalization of about $200 million. 23andMe had more than that amount of cash in the bank at the end of last quarter, meaning the company’s enterprise value is negative.
Snip...DNA tests aren’t as popular as they once were and lose money. Snip... since customers only need to take its test once.
Wojcicki pivoted the company into prescription drug development, hoping to use its massive DNA database to discover new pharmaceuticals. But drug discovery is a cash-hungry business in which prospects can take a decade to pay off. The company has enough cash to last until 2025 at its current rate of spending. It has potential drug candidates in the pipeline, and taking the company private while securing additional financing could give it more leeway to get them to market.
Snip...more...
https://archive.ph/WOUeO
https://www.wsj.com/tech/biotech/23andme-ceo-anne-wojcicki-plans-to-take-company-private-1a9265eb?mod=WTRN_pos2&cx_testId=3&cx_testVariant=cx_167&cx_artPos=1
❤️pants